Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**EleCeed** is a Columbia Care-developed, full-spectrum medical cannabis oral tablet containing equal quantities of delta-9-tetrahydrocannabinol and cannabidiol, plus 10 additional precisely formulated secondary cannabinoids. The patent-pending, pre-scored hard-pressed tablets were introduced as a long-lasting, precisely dosed product for medical-cannabis patients in New York. Delta-9-tetrahydrocannabinol principally activates cannabinoid receptors, while cannabidiol and the broader cannabinoid mixture may modulate cannabinoid signaling and other biological pathways. EleCeed was positioned for symptom management in chronic pain, neuropathy, epilepsy, multiple sclerosis, Parkinson's disease, rheumatoid arthritis, and Crohn's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EleCeed.